Clinical Trial Update: Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/2 study of the combination omacetaxine mepesuccinate and venetoclax in relapsed or refractory acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Biphenotypic Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Synribo (omacetaxine mepesuccinate)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-11-03